Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

12,012,000 7,440,000

Capital lease obligation, less current

portion 16,000 22,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock -- $.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock -- $.001 par value;

authorized 325,000,000 shares;

outstanding -- 226,210,617 and 226,210,617,

respectively 226,000 226,000

Additional paid-in capital 246,476,000 246,205,000

Accumulated deficit (235,922,000) (230,836,000)

Total stockholders' equity 10,780,000 15,595,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $22,808,000 $23,057,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED

July 31, 2008 July 31, 2007

Unaudited Unaudited

REVENUES:

Contract manufacturing revenue $1,193,000 $1,621,000

Government contract revenue 324,000 -

License revenue - 4,000

Total revenues 1,517,000 1,625,000

COSTS AND EXPENSES:

Cost of contract manufacturing 903,000 1,181,000

Research and development 4,068,000 3,624,000

Selling, general and administrative 1,706,000 1,708,000

Total costs and expenses 6,677,000 6,513,000

LOSS FROM OPERATIONS (5,160,000) (4,888,000)

OTHE
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , SAN FRANCISCO , Feb. ... ) acted as a placement agent in GenVec, Inc.,s (Nasdaq: ... shares of common stock, and warrants to purchase 4.2 million shares ... , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with ...
... ... for Manufacture and Testing of Drug Products Imported to the European Union. ... Toronto, Ontario (PRWEB) ... to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. ...
... , FORT LAUDERDALE, Fla. , ... published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrated ... and no late stent thrombosis at one year in ... percutaneous coronary intervention (PCI) and implantation of the company,s ...
Cached Biology Technology:Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 2Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 3OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Infection with West Nile virus (WNV) causes no symptoms ... encephalitis. What determines the outcome of infection with WNV in ... and colleagues, at the Blood Systems Research Institute, San Francisco, ... (immune cells that suppress the function of other immune cells) ...
... New Orleans, LA Dr. John England, Professor and ... analyzed research findings and was responsible for the quality and ... resulting in new guidelines for treating Lou Gehrig,s disease, or ... the October 13, 2009 issue of Neurology , the ...
... target to stem biodiversity loss by next year, according to ... to biodiversity science. The goal was agreed at ... Biological Diversity in April 2003. Some 123 world ministers ... current rate of biodiversity loss at the local, national and ...
Cached Biology News:LSUHSC's England plays key role in developing new ALS treatment guidelines 2World will miss 2010 target to stem biodiversity loss, experts say 2World will miss 2010 target to stem biodiversity loss, experts say 3World will miss 2010 target to stem biodiversity loss, experts say 4World will miss 2010 target to stem biodiversity loss, experts say 5World will miss 2010 target to stem biodiversity loss, experts say 6
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
Automated Cell Culture Flask...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: